Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is poised to fill a significant unmet need in schizophrenia treatment with its promising drug, roluperidone. However, the success of the drug remains uncertain and the company's value is heavily dependent on its effectiveness in improving negative symptoms. Investors should monitor the ongoing Phase 3 trial closely for any updates on the drug's efficacy and consider the potential impact of unproven financials on the company's valuation.

Bears say

Minerva Neurosciences is a clinical-stage biopharmaceutical company with a negative outlook, driven by doubts about the efficacy and market potential of its lead product candidate, Roluperidone, for treating negative symptoms in schizophrenia. Although Roluperidone has demonstrated potential in preclinical studies, the company's Phase 3 trials have failed to meet primary and secondary endpoints, and the drug has only shown a trend towards efficacy. Additionally, the company's current cash position and future funding needs create financial risk. Overall, the outlook for Minerva Neurosciences is uncertain, and its future success will depend on the results of its ongoing clinical trials and ability to secure funding for continued development.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.